Hormone replacement therapy

References

• Sherman BM, West JH, Korenman SG. The menopausal transition: analysis of LH, FSH, estradiol, and progesterone concentrations during menstrual cycles of older women. J Clin Endocrinol Metab 1976: 42(4): 629–36
   PubMed Web of Science ®Google Scholar
• Coope J. Double blind cross-over study of estrogen replacement therapy. In: Campbell S, ed. The management of the menopause & postmenopausal years. Lancaster, England: MTP Press, 1976: 159–68
   Google Scholar
• Geola FL, Frumar AM, Tataryn IV, et al. Biological effects of various doses of conjugated equine estrogens in postmenopausal women. J Clin Endocrinol Metab 1980: 51(3): 620–5
   PubMed Web of Science ®Google Scholar
• Youngblood VH, Tomlin EM, Davis JB. Senile urethritis in women. J Urol 1957: 78(2): 150–2
   PubMed Web of Science ®Google Scholar
• Beistand HO, Fossberg E, Moer A, et al. Urethral sphincteric insufficiency in post-menopausal females: treatment with phenylpropanolamine and estriol separately and in combination. A urodynamic and clinical evaluation. Urol Int 1984: 39(4): 211–6
   PubMed Web of Science ®Google Scholar
• Gambrell RD Jr. The menopause: benefits and risks of estrogen-progestogen replacement therapy. Fertil Steril 1982: 37(4): 457–74
   PubMed Web of Science ®Google Scholar
• Campbell S. Double blind psychometric studies on the effects of natural estrogens on post-menopausal women. In: Campbell, ed,2 pp 149–58
   Google Scholar
• Speroff L, Glass RH, Kase NG. Clinical gynecologic endocrinology and infertility. Baltimore: Williams & Wilkins, 1989: 138
   Google Scholar
• Weiss NS, Ure CL, Ballard JH, et al. Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen. N Engl J Med 1980: 303(21): 1195–8
   PubMed Web of Science ®Google Scholar
• Riggs BL, Seeman E, Hodgson SF, et al. Effect of the fluoride/calcium regimen on vertebral fracture occurrence in postmenopausal osteoporosis: comparison with conventional therapy. N Engl J Med 1982: 306(8): 446–50
   PubMed Web of Science ®Google Scholar
• Nachtigall LE, Nachtigall RH, Nachtigall RD, et al. Estrogen replacement therapy. II. A prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstet Gynecol 1979: 54(1): 74–9
   PubMed Web of Science ®Google Scholar
• Eaker ED, Castelli WP. Coronary heart disease and its risk factors among women in the Framingham study. In: Eaker ED, Packard B, Wenger NG, eds. Coronary heart disease in women: proceedings of an NIH workshop. New York: Haymarket-Doyma, 1987: 122–30
   Google Scholar
• Sullivan JM, Vander Zwaag R, Hughes JP, et al. Estrogen replacement and coronary artery disease: effect on survival in postmenopausal women. Arch Intern Med 1990; 150(12): 2557–62
   PubMedGoogle Scholar
• Rosenberg L, Armstrong B, Jick H. Myocardial infarction and estrogen therapy in postmenopausal women. N Engl J Med 1976: 294(23): 1256–9
   PubMed Web of Science ®Google Scholar
• Gruchow HW, Anderson AJ, Barboriak JJ, et al. Postmenopausal use of estrogen and occlusion of coronary arteries. Am Heart J 1988: 115(5): 954–63
   PubMed Web of Science ®Google Scholar
• Bush TL, Barrett-Connor E, Cowan LD, et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation 1987: 75(6): 1102–9
   PubMed Web of Science ®Google Scholar
• Bush TL, Barrett-Connor E. Noncontraceptive estrogen use and cardiovascular disease. Epidemiol Rev 1985: 7: 80–104
   Web of Science ®Google Scholar
• Stampfer MJ, Willen WC, Colditz GA, et al. A prospective study of postmenopausal estrogen therapy and coronary heart disease. N Engl J Med 1985: 313(17): 1044–9
   PubMed Web of Science ®Google Scholar
• Matthews KA, Meilahn E, Kuller LH, et al. Menopause and risk factors for coronary heart disease. N Engl J Med 1989: 321(10): 641–6
   PubMed Web of Science ®Google Scholar
• Jacobs DR Jr, Mebane IL, Bangdiwala SI, et al. High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women: the follow-up study of the Lipid Research Clinics Prevalence Study. Am J Epidemiol 1990;131(1): 32–47
   PubMed Web of Science ®Google Scholar
• Wilson PW, Garrison RJ, Castelli WP, et al. Prevalence of coronary heart disease in the Framingham Offspring Study: role of lipoprotein cholesterols. Am J Cardiol 1980: 46(4): 649–54
   PubMed Web of Science ®Google Scholar
• Barnes RB, Roy S, Lobo RA. Comparison of lipid and androgen levels after conjugated estrogen or depo-medroxyprogesterone acetate treatment in postmenopausal women. Obstet Gynecol 1985: 66(2): 216–9
   PubMed Web of Science ®Google Scholar
• Sorva R, Kuusi T, Dunkel L, et al. Effects of endogenous sex steroids on serum lipoproteins and postheparin plasma lipolytic enzymes. J Clin Endocrinol Metab 1988: 66(2): 408–13
   PubMed Web of Science ®Google Scholar
• Adams MR, Clarkson TB, Koritnik DR, et al. Contraceptive steroids and coronary artery atherosclerosis in cynomolgus macaques. Fertil Steril 1987: 47(6): 1010–8
   PubMed Web of Science ®Google Scholar
• Wilson PW, Garrison RJ, Castelli WP. Postmenopausal estrogen use, cigarette smoking, and cardiovascular morbidity in women over 50: the Framingham Study. N Engl J Med 1985: 313(17): 1038–43
   PubMed Web of Science ®Google Scholar
• Hassager C, Riis BJ, Strom V, et al. The long-term effect of oral and percutaneous estradiol on plasma renin substrate and blood pressure. Circulation 1987: 76(4): 753–8
   PubMed Web of Science ®Google Scholar
• Hassager C, Christiansen C. Blood pressure during oestrogen/progestogen substitution therapy in healthy post-menopausal women. Maturitas 1988: 9(4): 315–23
   PubMed Web of Science ®Google Scholar
• Wren BG, Roudedge AD. The effect of type and dose of oestrogen on the blood pressure of post-menopausal women. Maturitas 1983: 5(2): 135–42
   PubMed Web of Science ®Google Scholar
• Gambrell RD Jr. Prevention of endometrial cancer with progestogens. Maturitas 1986: 8(2): 159–68
   PubMed Web of Science ®Google Scholar
• Collins J, Donner A, Allen LH, et al. Oestrogen use and survival in endometrial cancer. Lancet 1980: 2(8201): 961–4
   PubMed Web of Science ®Google Scholar
• Creasman WT, Henderson D, Hinshaw W, et al. Estrogen replacement therapy in the patient treated for endometrial cancer. Obstet Gynecol 1986: 67(3): 326–30
   PubMed Web of Science ®Google Scholar
• Armstrong BK. Oestrogen therapy after the menopause: boon or bane? Med J Aust 1988: 148(5): 213–4
   PubMed Web of Science ®Google Scholar
• Dupont WD, Page DL. Menopausal estrogen replacement therapy and breast cancer. Arch Intern Med 1991: 151 (1): 67–72
   PubMedGoogle Scholar
• Steinberg KK, Thacker SB, Smith SJ, et al. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 1991: 265(15): 1985–90 [erratum, JAMA 1991: 266(10): 1362]
   PubMed Web of Science ®Google Scholar
• Hunt K, Vessey M, McPherson K, et al. Long-term surveillance of mortality and cancer incidence in women receiving hormone replacement therapy. Br J Obstet Gynaecol 1987: 94(7): 620–35
   PubMedGoogle Scholar
• Kakar F, Weiss NS, Strite SA. Non-contraceptive estrogen use and the risk of gallstone disease in women. Am J Public Health 1988: 78(5): 564–6
   PubMed Web of Science ®Google Scholar
• Rijpkema AH, van der Sanden AA, Ruijs AH. Effects of post-menopausal oestrogen-progestogen replacement therapy on serum lipids and lipoproteins: a review. Maturitas 1990: 12(3): 259–85
   PubMed Web of Science ®Google Scholar
• Stevenson JC, Cust MP, Gangar KF, et al. Effects of transdermal versus oral hormone replacement therapy on bone density in spine and proximal femur in postmenopausal women. Lancet 1990: 336(8710): 265–9
   PubMed Web of Science ®Google Scholar
• Williams SR, Frenchek B, Speroff T, et al. A study of combined continuous ethinyl estradiol and norethindrone acetate for postmenopausal hormone replacement. Am J Obstet Gynecol 1990: 162(2): 438–46
   PubMed Web of Science ®Google Scholar